Intas Pharmaceuticals Gets CDSCO Panel Nod to Study Vedolizumab for Ulcerative Colitis
New Delhi: Intas Pharmaceuticals has got the go-ahead from the Subject Expert Committee ( SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct a Phase III clinical trial to compare the efficacy, safety, immunogenicity, and pharmacokinetics of the proposed biosimilar of Vedolizumab (INTP53) Intravenous Injection and Vedolizumab reference for induction and maintenance therapy in patients with moderate to severely active ulcerative colitis.
This came after Intas Pharmaceuticals presented the proposal for grant of permission to conduct a Phase III clinical trial as per the protocol titled “A Phase III, Randomized, Double-Blind, Multicenter, Active-Controlled, Two-Arm, Parallel Group Study to Compare the Efficacy, Safety, Immunogenicity and Pharmacokinetics of the Proposed Biosimilar of Vedolizumab (INTP53) Intravenous Injection and Vedolizumab Reference for Induction and Maintenance Therapy in Patients with Moderate to Severe Active Ulcerative Colitis” vide protocol number: 0046-24 Version No.1.0, Dated 23-02-2024.
Vedolizumab is an integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults. Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative colitis or Crohn's disease.
At the recent SEC meeting on gastroenterology and hepatology held on July 25, 2024, the expert panel reviewed the proposal for grant of permission to conduct a Phase III clinical trial protocol presented by the drug major Intas Pharmaceuticals.
After detailed deliberation, the committee recommended conducting the Phase III clinical trial as per the protocol presented by the firm.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.